WIT DYNE(000915)2024-07-09 08:53Financial Performance - The company achieved total operating revenue of 1.154 billion yuan, a slight increase of 0.10% compared to the same period last year[2] - Net profit attributable to shareholders reached 331.87 million yuan, reflecting a growth of 3.12% year-on-year[2] - The pharmaceutical segment generated operating revenue of 1.136 billion yuan, with a net profit of 631 million yuan, marking increases of 0.44% and 0.32% respectively[3] - Basic earnings per share increased to 1.42 yuan, up by 3.65% from the previous year[2] - The net profit after deducting non-recurring gains and losses was 318.60 million yuan, an increase of 5.28% year-on-year[2] Asset and Equity Changes - Total assets decreased by 8.09% to approximately 4.778 billion yuan compared to the beginning of the period[2] - Shareholders' equity attributable to the company declined by 4.59% to approximately 2.845 billion yuan[2] - The company's net asset per share decreased to 12.14 yuan, down by 4.63% from the previous year[2] Return on Investment - The weighted average return on net assets decreased by 1.05 percentage points to 10.81%[2] Information Disclosure - The company emphasizes the importance of accurate information disclosure and warns investors of potential risks associated with preliminary financial data[1]